Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the effects of various formulations of progesterone on uterine electromyographic (EMG) activity in pregnant patients in premature labor to determine if progesterone will suppress uterine electrical activity and which formulation may be best for inhibition of uterine activity. Patients will be monitored prior to treatment and following treatment (every 2 to 4 hours) with one of three different formulations of progesterone for up to two days. Patients will continue to be observed until they deliver. Comparisons will be for uterine EMG activity from before treatment to that following treatments at 2, 4, 8, 12 24 and 48 hours and times of delivery after treatments (hours or days following treatments). Comparisons between mean values for EMG activity between the various treatments at the various times will also be made.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

NCT01206998

Labor, Premature

WITHDRAWN NA

Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor

NCT01840228

Premature Birth Obstetric Labor, Premature

TERMINATED NA

Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone

NCT01317225

Preterm Birth Obstetric Labor, Premature

UNKNOWN PHASE3

Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor

NCT02262481

Preterm Labor

COMPLETED NA

Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth

NCT02913495

Premature Birth

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study the investigators will compare the effects of vaginal progesterone, intramuscular applied progesterone and topical progesterone on uterine electromyographic activity (EMG)in patients in preterm labor. Electrodes will be placed on the abdominal surface of pregnant patients in preterm labor and the EMG activity recorded for 30 minutes before and following treatments for up to 48 hours. In addition data on delivery times will be recorded when patients delivery vaginally or by Cesarian section. Eligibility criteria: Healthy patients without infection or rupture of membranes with gestational ages between 24 to 34 weeks. Outcome measures: Comparisons of uterine EMG activity (EMG amplitude, frequency, and specific information on EMG bursts) from measurements before treatment to following treatments with progesterone preparations at various times (at 2,4,8, 12,24 and to 48 hours following treatment) and delivery times of patients on various treatments (hours or days following treatments, average delivery times in patients treated by various formulations). Comparisons of mean values in uterine EMG activity (EMG amplitude, burst frequency and frequency of signals in a burst, power spectrum analysis of the bursts and peak power density spectrum of bursts) from before treatment to following treatments at 2 to 24 hours will be compared. Also the time of delivery following treatments will be obtained and the average time of delivery following the various treatments compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Labor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaginal progesterone

vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)

Group Type EXPERIMENTAL

Experimental: Vaginal progesterone

Intervention Type DRUG

Vaginal progesterone formulation (150 mg micronized progesterone daily)

Topical progesterone

topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily

Group Type EXPERIMENTAL

Experimental: Topical progesterone

Intervention Type DRUG

Progesterone will be applied daily (150 mg micronized progesterone)by topical application

Intramuscular progesterone

injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)

Group Type EXPERIMENTAL

Experimental: Intramuscular progesterone

Intervention Type DRUG

Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental: Vaginal progesterone

Vaginal progesterone formulation (150 mg micronized progesterone daily)

Intervention Type DRUG

Experimental: Topical progesterone

Progesterone will be applied daily (150 mg micronized progesterone)by topical application

Intervention Type DRUG

Experimental: Intramuscular progesterone

Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prochieve, Columbia Laboratories No other name available Watson Laboratories

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy patients in preterm labor between 24 to 34 weeks of gestation presenting to St. Joseph's Hospital and Medical Center.
* Preterm labor is defined as at least 6 contractions in 60 minutes with a cervix either dilated to 2 centimeters or effaced to 80% and a cervical length measured by ultrasound of less than 3 centimeters, and a positive fetal fibronectin.
* Maternal ages will be within 17 to 40 year-old range.

Exclusion Criteria

* Patients with preterm premature rupture of membranes (PPROM) will be excluded from the study, due to possibility of ascending infection, as will those patients with suspected chorioamnionitis.
* Patients with medical conditions that contraindicate tocolysis, such as non-reassuring fetal heart tracings, will also be excluded.

Minimum Eligible Age

17 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes